Price$160.25+1.28 (+0.81%)
01:30 PM07:45 PM
News · 26 weeks125-17%
2026-04-122026-10-04
Mix6890d
- SEC Filings35(51%)
- Other26(38%)
- Analyst3(4%)
- Insider2(3%)
- Earnings1(1%)
- Offering1(1%)
Latest news
25 items- PRAstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts$1 billion investment will grow AstraZeneca’s workforce in Massachusetts by over 50% and deliver next-generation medicines AstraZeneca today announced the opening of its newest global strategic research and development (R&D) center, in Kendall Square, Cambridge, Massachusetts. The new state-of-the-art facility builds on the Company’s existing presence in Cambridge and Boston and places its scientists at the heart of one of the world’s most innovative life sciences ecosystems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005363276/en/AstraZeneca's Kendall Square Global R&D Center photo credit: Aram Boghosian Together with
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRAstraZeneca Completes $2 Billion Equity Investment in Summit TherapeuticsSummit Therapeutics Inc. (NASDAQ:SMMT) today announced the successful closing of AstraZeneca’s (NYSE:AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody. Pursuant to the terms of the Securities Purchase Agreement entered into by Summit and AstraZeneca, AstraZeneca purchased an aggregate of approximately 108,955 shares of preferred stock convertible into shares of common stock of Summit at a 1:1,000 ratio. The investment by AstraZeneca totaled $2.0 billion. At the conversion ratio, the investment represents a common stock pri
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRSummit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC DatrowayCollaboration Intends to Evaluate Ivonescimab in Combination with Datroway across Multiple Tumor Types Starting with a Phase III Study in First-Line Triple Negative Breast Cancer Summit Therapeutics Inc. (NASDAQ:SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (NYSE:AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with Datroway® (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate (ADC), across multiple solid tumor settings, intending to include breast and lung cancer. The companies intend to begin with a Phase III trial in first-line t
- PRDaiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor TypesDaiichi Sankyo (TSE: 4568) and AstraZeneca (NYSE:AZN) have entered into a clinical trial collaboration agreement with Summit Therapeutics Inc. (NASDAQ:SMMT) to evaluate Datroway® (datopotamab deruxtecan) in combination with ivonescimab across multiple tumor types including lung and breast cancers. The companies intend to begin with a phase 3 trial in first-line triple negative breast cancer (TNBC). Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. "At Daiichi Sankyo, we are focused on maximizing the potential of our DXd antibody drug conjuga
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRHigh-Stakes October has these Biotechs Entering Crucial StretchDENVER, Sept. 29, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- The biotechnology market is heading into a catalyst-heavy stretch, with Iovance Biotherapeutics (NASDAQ:IOVA), NeOnc Technologies Holdings (NASDAQ:NTHI), and Summit Therapeutics (NASDAQ:SMMT), moving from promises and pipelines toward events that could materially reshape how investors view their businesses. Iovance Boosts 2026 Revenue Guidance as Amtagvi Demand Surges For Iovance (NASDAQ:IOVA), the headline is revenue. The company raised its full-year 2026 total revenue guidance to $410 million to $420 million, up $55 million at the midpoint from its previous $350 million to $370 million range. That new outlook implies nea
- PRAstraZeneca Makes $2 Billion Strategic Equity Investment in Summit TherapeuticsInvestment in Preferred Shares Convertible to Common Equity, Equivalent to a Per-Share Price of Summit’s Common Stock of $18.36, Representing a Premium over Today’s Closing Trading Price Summit Also Enters into Clinical Trial Collaboration with AstraZeneca to Evaluate Ivonescimab in Combination with Sonesitatug Vedotin in Multiple Gastrointestinal Cancers Summit & AstraZeneca Plan to Enter into a Clinical Trial Collaboration Combining Ivonescimab with Multiple AstraZeneca ADCs and Other Cancer Medicines Summit Therapeutics Inc. (NASDAQ:SMMT) today announced key developments important to the company’s progress towards achieving its goal of making a significant difference in the lives o
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRPerioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancerBased on VOLGA Phase III trial results which demonstrated statistically significant and clinically meaningful improvements in event-free survival and overall survival AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in combination with enfortumab vedotin (EV) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or have declined cisplatin-based chemotherapy. The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available treatment options by demonstrati
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PREnhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast CancerRecommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi S
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- ANALYSTAstraZeneca upgraded by Deutsche BankDeutsche Bank upgraded AstraZeneca from Sell to Hold
- SECSEC Form 6-K filed by AstraZeneca PLC6-K - ASTRAZENECA PLC (0000901832) (Filer)
- PRENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial6-month improvement in median progression-free survival vs. pembrolizumab plus chemotherapy AstraZeneca and Daiichi Sankyo’s ENHERTU is the first HER2-directed therapy to delay disease progression over standard of care in a Phase III trial in this setting Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-m
- PRTAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trialLongest survival data ever reported in a global Phase III trial in this setting New data reinforce TAGRISSO as the standard of care and backbone therapy in EGFRm lung cancer across stages Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent. These results were presented today during the Presidential Symposium at the I
- PREnhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 TrialRepresents a six-month improvement in median progression-free survival versus pembrolizumab plus chemotherapy Daiichi Sankyo and AstraZeneca’s Enhertu is the first HER2 directed medicine to delay disease progression over standard of care in a phase 3 trial in this setting Positive results from the DESTINY-Lung04 phase 3 trial showed Enhertu® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a first-line treatment of patients with unresectable, locally advanced or metastatic HER2 mutant non-squamous non
- INSIDEROfficer Sharma Mani bought $3,249 worth of Ordinary Shares (20 units at $160.57) and was granted 1 units of Ordinary Shares, increasing direct ownership by 0.11% to 19,289 units (SEC Form 4)4 - ASTRAZENECA PLC (0000901832) (Issuer)
AZN FAQ
8 questionsWhat does AstraZeneca PLC do?
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir...Where does AZN stock trade?
AstraZeneca PLC (AZN) is listed on NYSE.What sector and industry is AZN in?
AstraZeneca PLC operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AstraZeneca PLC go public?
AstraZeneca PLC (AZN) completed its IPO in 2026.Does AZN pay a dividend?
AZN's most recent ex-dividend date was 2026-08-07 with a cash dividend of $1.06 per share. No future ex-date is on file yet.What are analysts saying about AZN?
AstraZeneca PLC has had 8 recent analyst actions on file. The most recent action was from Deutsche Bank: Hold on 2026-09-15.What companies are similar to AZN?
Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), NVS (Novartis AG), PFE (Pfizer Inc.), BMY (Bristol-Myers Squibb Company). Compare AZN side-by-side with any of them on Quantisnow.How can I track AZN on Quantisnow?
Quantisnow aggregates AstraZeneca PLC's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AZN to receive live email and push alerts on every new disclosure.